StockData
Grace Therapeutics, Inc. logo

Grace Therapeutics, Inc. (GRCE) stock

GRCENasdaqPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30
$1.72−0.03 (-1.71%)

Close on Nov 17, 2026Market cap $36.18MP/E –Yield –

Grace Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Grace Therapeutics's revenue for the twelve months ending Mar 31, 2022 was $100.00M, up 50920.4% year over year. For fiscal 2022 it was $100.00M, up 50920.4% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2022Mar 31, 2022$100.00M+50920.4%
FY2021Mar 31, 2021$196.00K–

Quarterly revenue

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2022CQ1 2022Mar 31, 2022$100.00M–
Q3 FY2022CQ4 2021Dec 31, 2021$0–
Q4 FY2021CQ1 2021Mar 31, 2021$115.00K–
Q3 FY2021CQ4 2020Dec 31, 2020$81.00K–

More Grace Therapeutics figures

See a number that looks wrong?